ELIEM THERAPEUTICS, INC.

Analyst Reco. Eliem Therapeutics, Inc.

Equities

ELYM

US28658R1068

Market Closed - Nasdaq Other stock markets 21:00:00 02/05/2024 BST			5-day change	1st Jan Change
8.39 ^USD	+10.83%		+147.49%	+210.74%

04-11	Sector Update: Health Care Stocks Softer Late Afternoon	MT
04-11	Top Midday Gainers	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Downgrades Eliem Therapeutics to Neutral From Buy	10/02/23	MT
HC Wainwright Starts Eliem Therapeutics at Buy With $6 Price Target	28/10/22	MT
SVB Securities Adjusts Eliem Therapeutics' Price Target to $4 From $9, Keeps Outperform Rating	16/08/22	MT
SVB Securities Adjusts Eliem Therapeutics' Price Target to $9 from $13, Keeps Outperform Rating	11/07/22	MT
Guggenheim Downgrades Eliem Therapeutics to Neutral from Buy	26/04/22	MT
SVB Leerink Lowers Price Target for Eliem Therapeutics to $13 From $33, Maintains Outperform Rating	25/04/22	MT
ELIEM THERAPEUTICS : Evercore ISI Initiates Coverage on Eliem Therapeutics With Outperform Rating	08/09/21	MT
ELIEM THERAPEUTICS : Stifel Starts Eliem Therapeutics at Buy with $35 Price Target	07/09/21	MT
ELIEM THERAPEUTICS : SVB Leerink Starts Eliem Therapeutics at Outperform with $33 Price Target	07/09/21	MT
ELIEM THERAPEUTICS : Guggenheim Starts Eliem Therapeutics at Buy with $32 Price Target	07/09/21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Discover our Free Content to Help You Better Understand the Stock Market.

100% Free Registration

fermer